The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

WCLC 2022 | Checkpoint inhibitors for lung cancer treatment

Name: Checkpoint inhibitors for lung cancer treatment
Uploaded: 2022-08-08T00:00:00Z
Duration: 56 s
Description: Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, talks on the introduction of checkpoint inhibitors into treatment landscape of lung cancer, and managing their associated toxicities. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.

Mirjana Rajer • 8 Aug 2022

WCLC 2022

Lung Cancer Checkpoint Inhibitors

Mirjana Rajer, MD, PhD, Institute of Oncology Ljubljana, Ljubljana, Slovenia, talks on the introduction of checkpoint inhibitors into treatment landscape of lung cancer, and managing their associated toxicities. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.